Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
December 10, 2024 09:00 ET
|
Novartis Pharma AG
Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between...
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
November 25, 2024 01:15 ET
|
Novartis Pharma AG
Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-year...
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
October 29, 2024 15:03 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III...
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
October 24, 2024 01:15 ET
|
Novartis Pharma AG
Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and indicated...
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
September 17, 2024 12:55 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for...
Tiny Health Appoints Dr. Elisa Song as Chief Medical Officer and Dr. Taylor Sittler as Board Director
September 17, 2024 09:53 ET
|
Tiny Health
Tiny Health appoints Dr. Elisa Song as Chief Medical Officer and Dr. Taylor Sittler as Board Director to strengthen its practitioner-focused strategy.
Foundation for Sarcoidosis Research Expands Scientific Advisory Board with 14 New Experts to Enhance Sarcoidosis Research and Patient Care
August 28, 2024 16:48 ET
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research appoints fourteen new members to serve the organization’s Scientific Advisory Board.
Tiny Health and Rupa Health Team Up to Transform Preventative Care
June 26, 2024 08:30 ET
|
Tiny Health
Partnership expands access to comprehensive at-home microbiome testing, aiming to address health issues at the root cause
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
May 30, 2024 18:01 ET
|
Novartis Pharma AG
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s...
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients
May 16, 2024 17:29 ET
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients